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Atherosclerosis is the hardening/thickening of the arteries (from Greek; arterio-
referring to the arteries and sclerosis-calcification/hardening). Arteries are often 
referred to as the “tubes” of the body, and these tubes can become narrowed due to 
accumulation of fat and calcification, leading to known diseases such as heart 
attacks and strokes. 
 
Atherosclerotic diseases are quite common and are a leading cause of morbidity and 
mortality in the western world. Accordingly, they contribute significantly to health care 
costs. An American survey has indicated that the prevalence of all cardiovascular 
disease will increase from 37% in 2010 to 41% in 2030, and the direct cost will 
increase from 273 billion dollars in 2010 to 818 billion dollars in 2030.[1] The 
American Heart Association has launched ambitious goals for treating and 
preventing cardiovascular disease.[2] In Norway, the prevalence of all cardiovascular 
disease isunknown, however a decline in mortality in cardiovascular diseases in 
Norway has been observed.[3] We do not have exact data regarding cardiovascular 
prevalence or mortality in our own region, but the latest registration of myocardial 
infarctions demonstrated a fairly stable incidence of 300/100 000 per year.  
Additionally, with the exception of elderly patients, a decline in mortality has also 
been observed.[4] 
 
Traditional risk factors for atherosclerosis include genetic predisposition, 
hypercholesterolemia, hypertension, diabetes, smoking, obesity, age and gender. 
There seems to be a shift in traditional risk factors globally as systolic hypertension 
is reduced[5], serum-cholesterol is modestly reduced[6] and there is an increase in 
body mass index.[7] Western countries have imposed stronger regulations leading to 
decreased use of tobacco, resulting in reduced coronary artery disease.[8] 
 
The development of an atherosclerotic lesion in the artery wall typically evolves over 
the course of years as demonstrated by several autopsy studies[9,10] and confirmed 
in a later ultrasound study.[11] Today there is consistent evidence that atherosclerosis 
starts with endothelial injury, adhesion of leukocytes to the endothelial layer, 
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migration of leucocytes to the intima of the arterial wall, formation of foam cells and 
further build up of an atherosclerotic plaque ([12] and Figure 1 below). Acute coronary 
events, including acute myocardial infarction, are most often caused by an imposing 
thrombus on the atherosclerotic plaque resulting from rupture of the thin fibrous 
cap.[13]  
 
The atherosclerotic spectrum is wide, ranging from acute coronary events such as 
unstable angina, myocardial infarction and sudden death to peripheral 





Figure 1. 1a shows the normal artery wall with the endothelial lining and the adventitia. 1b depicts the 
altered endothelium with adhesion of leukocytes, entering the intima with formation of cholesterol 
filled foam cells. 1c shows further development of the atherosclerotic plaque with influx of smooth 
muscle cells from the adventitia of the vessel wall. In 1d the final complication due to thrombosis 
resulting from rupture of the fibrous cap is shown. Reprinted by permission from Macmillan Publishers 
Ltd: Nature. Libby P, Ridker PM and Hansson G. Progress and challenges in translating the biology of 
atherosclerosis. Nature 2011;473:317-25. Copyright 2011.  
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1.2 Familial Hypercholesterolemia 
 
Familial hypercholesterolemia (FH) is an autosomal dominant inherited disease 
leading to high levels of low-density lipoprotein (LDL-) cholesterol and increased risk 
of premature atherosclerotic disease. 
 
1.2.1 Historical aspects/disease mechanism 
Although there are indications that the disease has been present for a long time [15], 
the link between lipid stigmata including xantomae and premature coronary artery 
disease was initially acknowledged in the first half of the twentieth century.[16-18] 
Several studies during the 1950s characterized the genetic features of the 
disease.[19,20] However, the landmark studies by Brown and Goldstein firmly 
documented the link between familial hypercholesterolemia and the structure of the 
LDL-receptor.[21-26] They demonstrated that mutations in the gene (chromosome 19) 
coding for the LDL-receptor led to reduced LDL-receptor activity and increased 
levels of LDL-cholesterol. The prevailing form of hypercholesterolemia is 
heterozygous in which approximately 50% of the LDL-receptors are missing. Other 
forms of autosomal dominant hypercholesterolemia have since been discovered, 
including those associated with apolipoprotein B mutations[27] or mutations in the 
gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9).[28]  In addition, 
a rare autosomal recessive form has been described.[29,30] 
The heterozygous form of FH (heFH) is quite common; most studies indicate a 
prevalence of 1/500 in white Caucasians[26], while subpopulations in certain parts of 
the world indicate a prevalence of 1/100 [31,32]. A Norwegian study found a 
prevalence of 1/300 in Østfold [33] estimating approximately 16500 persons with 
heFH in Norway today. Recent genetic testing has revealed 5273 positive FH 
mutation tests in Norway (TP Leren, personal communication, 27 October 2011).  
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1.2.2 Clinical features/diagnosis 
Persons with heFH have an increased risk of premature atherosclerosis compared 
with matched individuals without the disease. Before the statin-era (a statin is 
cholesterol lowering medication; the correct term is 3-hydroxy-3-methyl-glutaryl-CoA 
reductase inhibitors), approximately half of the men with FH had overt ischemic heart 
disease before the age of 50.[34] Later registry data have confirmed the increased 
risk of atherosclerotic disease associated with FH [35,36]; the risk seems reduced 
when treated adequately.[37-39] A recent non-invasive study has demonstrated 
substantial sub-clinical coronary artery disease in persons with FH, despite adequate 
treatment.[40] 
 
heFH leads to increased levels of LDL-cholesterol in the serum; this is a highly 
penetrating trait and in an adult population the LDL-cholesterol level is about 9 
mmol/L if no treatment is given.[26] A Norwegian study has shown that 
children/adolescents (2-18 years of age) have an average LDL-cholesterol of 5.6 
mmol/L.[41] This feature of elevated LDL-cholesterol may be the only manifestation of 
the disease during the first decade. Later on more typical stigmata such as arcus 






Xantoma in the achilles tendon, 
pathognomonic for FH. 
(Picture from the Lipid Clinic, 
Nordland Hospital) 
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The most frequent form of premature atherosclerosis in heFH is coronary heart 
disease ranging from stable angina to acute coronary syndromes including sudden 
cardiac death.[26] Furthermore, in heFH patients without symptoms of coronary artery 
disease, an invasive study has demonstrated more coronary atherosclerosis than in 
matched controls.[42] This finding was recently reproduced non-invasively.[40] Some 
data indicate that the risk of aortic root and valve disease is increased in heFH [43], a 
finding disputed by others.[44] 
 
Homozygotes in FH (hoFH) are rare (1/1000 000), and at this time there are 7 
patients with this diagnosis in Norway (Leiv Ose, personal communication 31 
October 2011). These patients have LDL-cholesterol levels ranging from 15 to 20 
mmol/L, and often have severe atherosclerotic complications in the first two decades 




There is general consensus that LDL-cholesterol reduction is mandatory in patient 
with FH.[46-48] This should be achieved with lifestyle modification and in most 
instances by means of statin therapy. A new European consensus paper also 
suggests that statin therapy should be started in children above the age of 10 with 
heFH and/or if the LDL- cholesterol is above 5 mmol/L.[49] 
The European treatment goal is LDL-cholesterol below 2.5 mmol/L[47], while the 
treatment goal in the US is an LDL-cholesterol reduction of more than 50% [48]. If 
statin therapy cannot be tolerated, bile acid sequestrants, ezetimibe or niacin are 
treatment options. If LDL-cholesterol levels cannot be controlled by means of 
medication, LDL apheresis is the next treatment step (see 1.4). New treatment 
options for elevated LDL-cholesterol including apolipoprotein B synthesis inhibitors 




1.3 Inflammation in atherosclerosis and FH  
Inflammation is closely linked to atherosclerotic diseases [51-53], and new data 
support that in patients with FH, the degree of inflammation is increased.[54,55] 
Accordingly, statins, the most widely used drug for FH treatment have been shown to 
reduce inflammation.[56,57] Our group has accordingly shown that statin-treated FH 
patients have the same inflammatory profile and endothelial function as controls.[58] 
Previously there have been few cross-over studies on how different LDL apheresis 
columns affect inflammation. 
 
 
1.3.1 The complement system and atherosclerosis 
The complement system is part of our innate defence against infections and consists 
of about 30 proteins mainly secreted by hepatic cells and monocytes. While 
complement is a “resting defence”, it can quickly be activated by events such as 
infections or detection of foreign surfaces. There are three different mechanisms by 
which the complement system can be activated via the classical pathway (CP), the 
mannose binding lectin pathway (MBL) and the alternative pathway (figure 3). These 
different activation paths lead to a common pathway involving formation of C3a and 
C5a and other split products. From this point, the cascade continues to the terminal 
pathway with resulting lysis of the target cell (figure 3). The complement system is 
central in the pathophysiology of several diseases including atherosclerosis [59] which 
it can both promote and protect against.[60-62] More specifically, it has recently been 
demonstrated that a polymorphism in complement factor H (Y402H) decreases 











Figure 3 shows the three different paths leading to activation of the complement system, the common 
pathway, and finally to formation of the terminal complement complex “Reprinted from Trends 
Immunol, 23:61-63, Mollnes TE, Song WC and Lambris JD. “Complement in inflammatory tissue 




1.3.2 Cytokines and atherosclerosis 
Cytokines are small proteins functioning as signalling molecules in the nervous- and 
the immune system.  Cytokines can be categorized as pro-inflammatory, and hence 
pro-atherosclerotic, or anti-inflammatory.[52,64,65] There are data supporting that 
untreated FH patients have a pro-inflammatory cytokine profile.[54,66,67] Few studies 
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1.4 Hemostasis and atherosclerosis 
Previous studies have shown that factors important in hemostasis, including 
fibrinogen and plasminogen activator inhibitor-1 (PAI-1), are associated with 
increased risk of coronary artery disease.[68-71] However, these factors have not been 
associated with increased risk of coronary artery disease in a cross section of 
patients with treated familial hypercholesterolemia.[72] There are few prospective data 
on the effect of LDL apheresis regarding these parameters. 
 
1.5 Lipoprotein (a) and familial hypercholesterolemia 
The Lipoprotein(a) [Lp(a)] particle is a complex of a hydrophobic LDL-cholesterol-
particle and a hydrophilic apolipoprotein(a) [Apo(a)] –particle. The isoforms and thus 
the size of apo(a) depend on the number of so-called kringle 4 (K 4) repeats.[73] Risk 
of atherosclerosis is associated with levels of Lp(a), and smaller isoforms are 
thought to be more atherogenic.[74-76] Lp(a) level is thought to be an important risk 
factor for atherosclerosis for individuals with FH.[77,78] Standard lipid lowering 
therapy, however, has failed to lower Lp(a) levels.[79] There is ample evidence that 
LDL apheresis lowers Lp(a) effectively [80,81], however there are few prospective 
studies where evaluation of the effect on the size of the Lp(a) particles have been 
performed.   
  
1.6 LDL apheresis in FH 
LDL apheresis is an extracorporeal treatment in which the patient´s blood is passed 
through an apheresis machine with filters/columns that selectively remove the LDL-
cholesterol, resembling how a patient with renal failure is treated with hemodialysis 
to clear “waste products”. The procedure is performed in specialist centers 
throughout the world, when the LDL levels cannot be controlled with medications 
alone, or when patients cannot tolerate the medication. 
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1.6.1 Apheresis in clinical medicine/historical aspects 
Apheresis was first performed in Paris in 1967 by means of plasma exchange with 
removal of serum cholesterol[82], and was first described in the English literature in 
1975.[83] The technique has since evolved from non-specific plasma exchange to 
more selective LDL-cholesterol removal. Some advocate use of the term lipid 
apheresis, as several lipoproteins are removed including chylomicrons, very low-
density lipoprotein (VLDL) and LDL-cholesterol.[80] Most systems used today utilize a 
column that “selectively” removes LDL-cholesterol from blood or from plasma. 
Venous access is needed, either through a venous catheter or through an 
arteriovenous (A-V) fistula. Anticoagulation is mandatory during treatment. LDL 
apheresis has also been used in order to remove Lp(a) as mentioned above (1.3), 
and there are some case reports on using LDL apheresis to lower elevated 














Figure 4. Schematic drawing of LDL apheresis. Blood is passed from the 
patient through a central line or an A-V fistula, through the apheresis 
system. In the example shown, blood is passed through a plasma 
separation column, and the plasma is then passed through the LDL 
apheresis column removing the lipoproteins. The ”rinsed” plasma is then 
mixed with the cellular components before being returned to the patient. 











1.6.2 LDL apheresis in FH 
There is general agreement that LDL apheresis should be used in patients with FH 
when LDL-cholesterol levels cannot be otherwise controlled.[46,48,85,86] In the US, the 
Food and Drug Administration has approved LDL apheresis for the following 
indications: 
 
• FH homozygotes with LDL-cholesterol > 12.8 mmol/L 
• FH heterozygotes with LDL-cholesterol > 7.7 mmol/L 
Figure 5. Photograph of an LDL apheresis system. The arrow to the left 
denotes the plasma separation column, while the dashed arrow to the right 
denotes the LDL apheresis column. 
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• FH heterozygotes with LDL-cholesterol >5.1 mmol/L if they have concomitant 
coronary artery disease 
 
The British, German and international criteria are quite similar.[87] 
 
1.6.3 Possible unwanted effects of the treatment 
Side effects occur with all types of treatment and in a small clinical study, our group 
found a high proportion of reported side effects in LDL apheresis.[88] As we pointed 
out in a current review, even if the treatment seems well tolerated, further 
prospective studies need to be carried out in this field.[89] This is mainly due to the 
fact that many of the studies report different kinds of apheresis treatment (other than 
LDL apheresis) together with LDL apheresis. The proportion of side effects varies 
widely between the centers, suggesting that side effects are not registered uniformly. 
This area of research concerning side effects should be further explored as 
apheresis is administered weekly, and possibly for the life of the patient.  
 
1.6.4 Biocompatibility regarding LDL apheresis  
“Biocompatibility refers to the ability of a biomaterial to perform its desired function 
with respect to a medical therapy, without eliciting any undesirable local or systemic 
effects in the recipient or beneficiary of that therapy, but generating the most 
appropriate beneficial cellular or tissue response in that specific situation, and 
optimizing the clinically relevant performance of that therapy”.[90] Thus when 
performing extracorporeal treatment such as LDL apheresis, it becomes paramount 
that the interaction between blood and biomaterials does not elicit any unwanted 
responses. Along these lines, in addition to LDL-cholesterol lowering, apheresis 
should be beneficial to the patient with regard to total lipid profile (beyond LDL-), 
complement activation, cytokine response, and hemostatic and fibrinolytic factors. 
Biocompatability as such, for the patient receiving LDL apheresis, concerns the 
achievement of a beneficial lipid-, complement-, cytokine-, hemostatic and fibrinolytic 
response, all of which are clinically relevant for patients prone to atherosclerotic 
diseases. Several studies have shown that complement activation precedes later 
inflammatory responses [91-94], and the complement system is therefore of particular 
interest in biocompatibility studies. 
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1.6.5 Concluding remarks on previous studies of LDL apheresis  
There are numerous studies on LDL apheresis (using this term in a Medline search 
retrieves 1083 results (1st November 2011). Most of the studies have focused on 
efficacy regarding LDL-cholesterol lowering. However, many of these studies are 
retrospective, small and address different kinds of patients (both hoFH and heFH 
patients and sometimes also familial combined hyperlipidemia). There are very few 
studies that prospectively compare different types of LDL apheresis 
columns/systems with regard to complement, cytokines, hemostasis, fibrinolysis and 
Lp(a) in a controlled population with heFH and thus exploring biocompatibility issues.  
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2 Aims of study 
 
2.1 General aims 
The general aim of the study was to explore, in a prospective manner, how three 
different LDL apheresis columns/systems affected complement, cytokines, 
hemostasis, fibrinolysis and Lp(a) in a group of patients with genetically proven 
heFH. Secondly, we wanted to study biocompatibility issues raised by the clinical 
study in an ex vivo setting. 
 
  
2.2 Specific aims 
Paper I 
The aim of the first paper was to explore how three different LDL apheresis columns 
(DL-75, LA-15 and EC-50W) affected lipoprotein proportions, sensitive CRP, 
complement activation products and cytokine profile in a clinical in vivo setting 
including a group of patients with FH. 
 
Paper II 
The aim of the second paper was to explore how DL-75, LA-15 and EC-50W 
columns affected hemostatic and fibrinolytic parameters in vivo in the same group of 
patients with FH. 
 
Paper III 
The aim of the third clinical paper was to explore how the three LDL apheresis 
columns affected the levels of Lp(a) during treatment, and if the isoform of the 
apolipoprotein was important with regard to Lp(a) lowering in vivo, in the same 
patients described above. 
 
Paper IV 
The aim of the fourth paper was to address biocompatibility regarding the DL-75, LA-
15 and EC-50W columns with complement activation as the read-out, and hence to 
address the “complement compatibility” of the three columns in a closed circuit ex 
vivo model with freshly donated blood from healthy donors. Complement was chosen 
as read-out, in the first of several ex-vivo papers as complement activation in 
! 19!
previous studies have been shown to precede other inflammatory responses in a 
number of settings 
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3 Materials and Methods 
 
3.1 Paper I-III 
The first three papers were based on a clinical trial including three patients with 
known heFH (from mutation testing), all three established in LDL apheresis in our 
Department of Nephrology/Department of Cardiology/Lipid Clinic due to intolerance 
to statins (muscle pain) before the study. Therefore the number of patients was low, 
but at the time of the study our hospital was the largest center for LDL apheresis in 
Norway, illustrating the challenge in performing systematic studies on this topic. 
Furthermore, we took a number of methodological measures to counteract the 
limited number of participants. All apheresis treatments were performed in one site, 
by an experienced/consistent group of apheresis nurses and doctors. 
All the lab samples were handled systematically, and in the same way, with short 
distance (three minutes walking) to the research lab for further handling by 
experienced research staff. The patients had six treatments with each different LDL 
apheresis columns (DL-75, LA-15 and EC-50W), thus there were 18 samples taken 
before and after apheresis for each of the three patients. A prospective cross-over 
design was chosen, with random order for each patient in order to minimize carry-
over effects. 
 
Before and after treatment comparisons for two groups were carried out by means of 
T-test, while comparisons of more than two groups were done by means of ANOVA. 
If groups were not equally distributed, non-parametric statistics was chosen.   
 
3.2 Paper IV 
In the clinical study we noted activation of the complement system including 
differences between the columns. However the site-, the degree of- and the time 
course of complement activation were not known. This prompted us to carry out an 
ex vivo experiment in which healthy donor blood was passed through the same 
columns we tested in the clinical study. Blood from six donors was passed through 
the columns (DL-75, LA-15 and EC-50W) three times, thus there were a total of 18 
experiments; six for each column. During each ex vivo procedure, samples were 
taken at different sites (two to four sites, depending on the column type (plasma 
! 21!












Figure 6. Schematic ex vivo apheresis. 6A demonstrates the whole 
blood system with sampling before and after the LDL apheresis 
column. 6B shows the two plasma separation systems (LA-15 and 
EC-50W), in which samples were drawn before and after both the 
plasma separation columns and the apheresis columns. 
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4 Summary of main results 
4.1. Paper I 
In this paper we found that while all columns reduced LDL-cholesterol significantly, 
the three columns affected the complement system and cytokine activity differently. 
LDL-cholesterol was reduced by 67%, 75% and 68% by columns DL-75, LA-15 and 
EC-50W (all p<0.001), and sensitive C-reactive protein (CRP) was reduced with 
77%, 72% and 43% for the same columns respectively (all p<0.001). TCC increased 
equally for all columns indicating that the complement cascade was activated to 
completion for all systems. There was a substantial increase in fragment Bb, 
reflecting alternative complement activation, while C4d was only marginally affected. 
The anaphylatoxins C3a and C5a were lowered more with the adsorption columns 
DL-75 and LA-15 than with the filtration column EC-50W. Accordingly, the adsorption 
columns DL-75 and LA-15 behaved similarly regarding cytokines, while the filtration 
column EC-50W tended to differ from the two other systems by statistical analyses. 
Some of the pro-inflammatory cytokines (RANTES and TNF-α) were reduced more 
by the adsorption- than filtration columns.  
    
 
4.2 Paper II 
This paper focused on the hemostatic changes in LDL apheresis in the clinical study, 
and there were differences between the three columns. Fibrinogen was reduced 
significantly for all columns; 28%, 32% and 48% for columns DL-75, LA-15 and EC-
50W respectively. EC-50W was most effective when comparing all columns. 
Thrombin-antithrombin (TAT) increased with all columns, and TAT increased the 
most with DL-75, and the least with LA-15. Plasminogen activator inhibitor-1 (PAI-1) 
was reduced with all columns, especially for DL-75 which was significantly different 




4.3 Paper III 
Paper III demonstrated that all the columns lowered Lp(a) significantly,  (p<0.001); 
70%, 74% and 75% for columns DL-75, LA-15 and EC-50W respectively without 
significant differences between the columns. The three patients had dominating 
small isoforms of Apo(a); 14 and 32 K 4 domains, and the apheresis treatment did 
not affect the relative proportion of the two isoforms. The reduction in Lp(a) 




4.4 Paper IV 
In the experimental ex vivo study we found that the apheresis columns used in the 
clinical studies affected complement activation and complement factors differently. 
Regarding the final common terminal complement complex (TCC), DL-75 was inert 
while the two plasma separation based systems (LA-15 and EC-50W) generated 
substantial amounts of TCC. Classical pathway activation was revealed by C4d and 
C1rs-C1inhibitor complexes for the plasma separation systems, while activation 
through the alternative pathway, measured by Bb, was most pronounced for LA-15. 
The anaphylatoxins C3a and C5a were equally induced by the plasma columns of 
LA-15 and EC-50W, however they were more efficiently cleared by the LA-15 














5.1 Complement activation (paper I and IV) 
Several papers have emphasized the importance of the complement system in the 
evolvement of atherosclerosis.[60-62,95] Formation of TCC via the final common 
pathway is associated with atherosclerosis.[62] Activation of the complement system 
via the alternative pathway appears to be pro-inflammatory, whereas activation via 
the classical/lectin pathways appears to be protective.[62] The anaphylatoxins C3a 
and C5a are pro-inflammatory, and indeed C5a has been associated with plaque 
ruptures[95] known to lead to clinical events such as acute myocardial infarctions. 
Furthermore, it has been shown that the degree of complement activation measured 
by TCC is inversely correlated with outcome in the acute clinical setting.[96] 
 
TCC 
Fadul et al. have previously shown that in clinical LDL apheresis in hoFH patients 
(plasma separation before apheresis), TCC increases after the plasma separation 
column and decreases after the LDL apheresis column, suggesting adsorption.[97] In 
our clinical study (paper I) we found an increase in TCC for all columns in patients 
(AV-fistula) immediately after completion of LDL apheresis. The treatment time 
differed between the two studies, as did the form of FH, with our study involving only 
heFH. However, the findings suggest that extracorporeal treatment in the form of 
LDL apheresis induces complement activation to completion.  In the ex vivo study, 
we were able to examine the changes in complement in greater detail due to the use 
of several sampling sites and several sample times. Clearly, TCC increased 
substantially after the plasma separation columns in LA-15 and DL-75, but all the 
LDL apheresis columns (DL-75, LA-15 and EC-50W) seemed to clear TCC from the 
circulation over time. Accordingly, after 120 minutes the pre-return values of TCC 
were quite similar between the three systems, but during the first 120 minutes the 
TCC returned to the patient was systematically higher with the two plasma 
separation based systems than with the whole blood system DL-75, suggesting 
lesser complement activation with the latter.  
Therefore, over time, both LA-15 and EC-50W seem to clear the TCC produced as a 
result of activation in the plasma separation columns. However, this could also be a 
result of eventual coating of the apheresis columns over time, resulting in attenuation 
of the complement activation analogue.  This is consistent with studies describing 
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the “first pass syndrome” in which allergic reactions to hemodialysis membranes 
were reduced with repetitive use.[98]  
 
Complement Activation Pathway 
Several studies indicate that the alternative pathway (AP) of complement activation 
is important when foreign surfaces interact with blood [99-101], even if other pathways 
are also important when considering biomaterials used in medicine.[102] In our clinical 
study (paper I) we found evidence for activation through the alternative pathway for 
all columns, especially for the plasma separation based systems.  However, only 
marginal changes in C4d were observed, suggesting that the classical/lectin 
pathways were of lesser importance. Our ex vivo study, however, demonstrated that 
in addition to activation through the alternative pathway, the classical pathway was 
also important. There was an increase in C4d for both plasma separation columns, 
but not so for the whole blood column. The increase in C4d correlated positively with 
C1rs-inh, suggesting activation via the classical pathway. The EC-50W column 
cleared C4d to the least degree, and thus had higher pre-return values of C4d than 
the other columns. Activation through the classical pathway is traditionally thought to 
be dependent on antibodies, possibly suggesting binding of antibodies to the plasma 
separation columns. In addition, other mediators such as CRP, beta-amyloid and 
polyanions may also be able to induce this system.[59] The clinical meaning of this 
finding is not obvious as activation through the classical/lectin pathways are 




Fadul et al. showed that the anaphylatoxin C3a increased significantly after the 
plasma separation column, but decreased after the LDL apheresis column.[97] In our 
clinical study we found that C3a increased for all the columns after treatment, while 
C5a decreased after treatment. The highest increase in C3a and lowest reduction in 
C5a was shown for the filtration column EC-50W, and thus the EC-50W column was 
least beneficiary with regards to the anaphylatoxins which are regarded as pro-
atherogenic.[62,95] In the ex vivo study (paper IV) the same tendency observed for 
TCC was seen here.   That is, low levels of C3a and C5a for the whole blood system 
were observed while the two plasma separation systems increased C3a and C5a 
substantially. 
The adsorption column LA-15 removed these anaphylatoxins over time, reducing 
pre-return values. However, the filtration column EC-50Wwas not able to lower the 
concentration of C3a and C5a, leading to higher levels of pre-return C3a and C5a. 
This could be important to individual patients with high risk of atherosclerotic disease 
as indeed is true of patients with heFH.[38,39] In accordance with this, a recent paper 
has demonstrated that high levels of C3a and C5a increase the risk of lumen 
reduction after implantation of drug eluting stents in the coronary arteries.[103]  
 
Bicompatability 
When utilizing artificial surfaces during blood-biomaterial interaction as a part of LDL 
apheresis, it is important that other constituents of the blood are not affected in an 
adverse manner as iterated in the new definition of biocompatibility (section 1.6.4, 
page 19). Because complement activation precedes other inflammatory responses, 
we chose complement as the read-out. We found that the whole blood column DL-75 
is an inert column with regard to complement activation, and is thus more 
complement compatible than the other two columns. The filtration column EC-50W is 




5.2 Sensitive CRP and cytokines (paper II) 
Some data indicate that CRP could be causative with regard to atherosclerosis 
[104,105], but data are conflicting and a consensus has yet to be established.[106,107] 
The JUPITER Trial clearly demonstrated that clinical end-points were reduced along 
with reductions in CRP and LDL-cholesterol in healthy persons with LDL-cholesterol 
below 3.4 mmol/L and CRP below 2 mg/L.[108] Previous studies on LDL apheresis 
have demonstrated reductions in CRP levels.[109-111] We found a decrease for all 
columns, especially for DL-75 and least for EC-50W. Whether or not reduction in 
CRP during apheresis is beneficial regarding clinical endpoints remains to be 
determined in larger clinical trials. 
 
Several cytokines correlate with risk of atherosclerosis [52,64], and previous studies on 
apheresis have indicated that LDL apheresis columns affect cytokine levels.[112,113] In 
our clinical study (paper I) we found a significant decrease in the amount of pro-
inflammatory cytokines; TNF-α and RANTES, and an increase in the amount of anti-
inflammatory cytokines IL-1ra and IP-10. The adsorption columns DL-75 and LA-15 
had a more beneficial profile than the filtration column EC-50W, with regards to the 
pro- and anti-inflammatory cytokines. According to this; DL-75 and LA-15 were more 
biocompatible than EC-50W with regard to cytokine response. Adsorption of 
cytokines has been characterized in sepsis[114] and Stefanutti et al. later reported on 
the cytokine profiles before and after LDL apheresis by means of plasma adsorption 
columns in patients with hoFH.[115] They found a decrease in TNF-α, and a decrease 
in IL-10 with no change in IL-1ra. Therefore the reduction in TNF-α is similar to our 
results, while changes in the anti-inflammatory cytokines differ, as do the results 
when comparing with LA-15 (plasma separation and adsorption). It is possible that 
some of these changes could be explained by different methodology, and the fact 
that our study observed heFH while Stefanutti et al. examined hoFH. Recent reviews 
have proposed that some of the beneficial effects of LDL apheresis on clinical end-
points may be due in part to modulation of pro-inflammatory biomarkers.[116,117] 
 
5.3 Markers of hemostasis (paper II) 
Previous studies have established that LDL apheresis lowers fibrinogen [112,118], 
despite some differences between the columns.[118] We found that all columns 
lowered fibrinogen, especially for the filtration column EC-50W. However, the level of 
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fibrinogen is closely tied to other risk markers for atherosclerosis[119], so the net 
effect of fibrinogen lowering in LDL apheresis should be further tested. 
 
A recent study has shown that PAI-1 is reduced in LDL apheresis[120], and a pilot 
study showed that TAT was suppressed during apheresis, while post apheresis 
values were elevated compared to baseline.[121] We noted a decrease in PAI-1 for all 
columns, the largest reduction were in the adsorption columns DL-75 and LA-15, and 
the least reduction was observed in the filtration column, whereas the least increase 
in TAT was found in the adsorption column LA-15. Few studies have systematically 
compared the effect of different apheresis columns on these hemostatic markers, 
and our findings indicate that the adsorption column, LA-15, is the more 
biocompatible column with regard to hemostatic and fibrinolytic parameters. Recent 
data indicate that PAI-1 is pivotal in development of coronary thrombus, underlying 
acute coronary events.[122] However, the prognostic value of this marker is 
uncertain.[123] It has also been shown that formation of TAT complexes is increased 
in patients with acute myocardial infarction when compared to stable coronary artery 
disease.[124] It has also been demonstrated that previous cholesterol lowering by 








5.4 Lipoprotein (a) (paper III) 
Reduction of Lp(a) with lipid apheresis has consistently reduced clinical endpoints in 
patients with coronary artery disease and elevated levels of Lp(a) [126]. Studies 
examining the effect of LDL apheresis on Lp(a) levels have typically reduced Lp(a) 
by 60 to 80 percent[81,127]. We found a similar 70-75% reduction in Lp(a) and there 
were no inter-column differences. This is within threshold reduction (70%) when 
treating patients with FH and elevated Lp(a) as recommended by Borberg et al.[127] 
In addition to the level of Lp(a) in each patient, the size of the Lp(a) particle is also of 
importance regarding the risk of atherosclerotic complications.[75,76] The Lp(a) 
particle is a complex of a hydrophobic LDL-particle and a hydrophilic 
apolipoprotein(a) [Apo(a)] -particle, and furthermore the isoforms, and thus the size 
of Apo(a), depend on the number of so-called kringle 4 (K 4) repeats.[73] The isoform, 
and hence size of the Apo(a) particle, is associated with risk of cardiovascular 
disease.[76] Therefore, our finding of equal reduction of Lp(a) in heFH patients with 
small Lp(a) particles may be of clinical importance. At the present time, with regard 
to clinical endpoints, no randomized study has been conducted with LDL apheresis 
on patients with heFH and elevated Lp(a). Also, a recent review on this subject 
concludes that apheresis is an important treatment modality in both FH and elevated 




6.1 Main Conclusions 
• LDL-cholesterol was lowered significantly and to the same extent by the LDL 
apheresis columns DL-75, LA-15 and EC-50W in a group of patients with 
heterozygous familial hypercholesterolemia. 
• The clinical study showed that the complement cascade was activated 
through the alternative pathway, while the ex vivo study indicated activation 
through the classical pathway as well. The adsorption columns DL-75 and LA-
15 cleared the anaphylatoxins C3a and C5a more effectively than the filtration 
column EC-50W in the clinical study. This finding was reproduced in the ex-
vivo study, and thus the adsorption columns DL-75 and LA-15 exhibit greater 
complement compatibility. 
• The adsorption columns DL-75 and LA-15 were less pro-inflammatory 
regarding cytokines and sensitive CRP than the filtration column EC-50W. 
• EC-50W reduced fibrinogen the most, while LA-15 increased TAT the least, 
and DL-75 reduced PAI-1 the most, thus the least hemostatic column could 
not be identified in this study. 
• All columns reduced Lp(a) significantly and to the same extent in this group of 




6.2 Unresolved questions/directions of future research 
• The findings of the clinical study should be reproduced in a larger number of 
heFH patients with a multi-center design if possible. 
• The magnitude of adsorptive properties of the different columns could be 
studied ex vivo after stimulation of complement and cytokine production. We 
have planned such an experiment. 
• The “up-stream” effect of complement activation with regard to inflammatory 
responses should be further explored, and we are currently conducting such 
a study. 
• The effects of altered immunological and hemostatic responses with the 
different LDL columns should be studied with regard to clinical endpoints. 
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• The clinical relevance of activation of the complement system should be 
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